Improving Lives Through Nuclear Medicine™

Educational Resources

TIME Thyroid Cancer Education

TIME to Decide What Is Right for Your Patients

TIME is a program developed to improve patients’ understanding of thyroid cancer treatment options and to help guide your patients’ decision making.

TIME Education Resources for Physicians

To learn more about these resources or to order copies, please email TIME@jdi.jubl.com

Physician/Patient Flip Chart
In-office discussion aid that helps facilitate conversations with patients, from initial diagnosis through treatment and long-term monitoring

Informed Consent for Low-Risk Thyroid Cancer
An article by M. Sara Rosenthal and colleagues, housed in a reprint carrier that provides an overview of the topic and how to put it into practice

Thyroid Cancer Treatment Roadmap
At-a-glance infographic explaining thyroid cancer diagnosis and treatment options.

TIME Education Resources for Patients

The following materials have been developed for patients:

Thyroid Cancer Treatment Road Map
An at-a-glance infographic explaining thyroid cancer diagnosis and treatment options. View PDF

Radioactive Iodine (Iodine-131): What to Expect
A guide for patients on considerations before, during, and after treatment. View PDF

Radioactive Iodine (Iodine-131): Fact vs Fiction
A useful list dispelling common misconceptions patients may have about Iodine-131. View PDF

Informed Consent Guide
A review of important points you should consider before making treatment decisions with their doctors. View PDF

Radioactive Iodine (Iodine-131) Video
Highlights how and why radioactive iodine (Iodine-131) is used. Includes commentary from the perspective of physicians, and patients who have received I-131 therapy. Watch Video

Other Educational Resources

For thyroid cancer support groups, educational events, videos, education materials, and more patients’ resources, visit:

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.